Jama 2008, 300:2277–2285.PubMedCrossRef 13. Higgins JPT, Green S: Cochrane handbook for PF299804 Systematic Reviews of intervention 4.2.6 [updated sep 2006]. In The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd; 2006. 14. Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R: Interpreting measures of treatment effect in cancer clinical trials. Oncologist 2002, 7:181–187.PubMedCrossRef 15. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, Sperduti
I, Carlini P, Terzoli E, Cognetti F, Giannarelli D: Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: Meta-analysis of randomized clinical trials. Lung Cancer 2008. 16. Parmar MKB, Machin D: Survival analysis: a practical approach. Chichester (England): John Wiley; 1995. 17. Altman DG: Confidence intervals for the number needed to treat. Bmj 1998, 317:1309–1312.PubMed 18. Giantonio Ruxolitinib supplier BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin
Oncol 2007, 25:1539–1544.PubMedCrossRef click here 19. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22–28.PubMedCrossRef 20. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pinter T, Lim R, Bodoky G, et al.: Cetuximab and chemotherapy Reverse transcriptase as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408–1417.PubMedCrossRef 21. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326–5334.PubMedCrossRef
22. Bria E, Di Maio M, Carlini P, Cuppone F, Giannarelli D, Cognetti F, Milella M: Targeting targeted agents: open issues for clinical trial design. J Exp Clin Cancer Res 2009, 28:66.PubMedCrossRef 23. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697–3705.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions FL, EB, VV and FC participated in the conception and the design of the analysis; EB, FC, IS and DG performed the statistical analysis. FL, EB, VV, CC, and LS revised the whole writing process.